Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study

被引：0
|
作者：
Zhong, Nanshan [1 ]
Wang, Changzheng [2 ]
Zhou, Xiangdong [3 ]
Zhang, Nuofu [1 ]
Patalano, Francesco [4 ]
Humphries, Michael [5 ]
Wang, Linda [5 ]
Banerji, Donald [6 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China
[2] Third Mil Med Univ, Xin Qiao Hosp, Inst Resp Dis, Chongqing, Peoples R China
[3] Third Mil Med Univ, Southwest Hosp, Dept Resp Med, Chongqing, Peoples R China
[4] Novartis Pharma AG, Resp, Basel, Switzerland
[5] Beijing Novartis Pharma Co Ltd, Resp, Beijing, Peoples R China
[6] Novartis Pharmaceut, Resp, E Hanover, NJ USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2015年 / 46卷
关键词：
COPD; -; manag; ement; Bronchodilators; Treatments;
D O I：
10.1183/13993003.congress-2015.PA990
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA990
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Once-Daily QVA149 Demonstrates Superior Improvements in Patient-Reported Dyspnea Compared to Tiotropium in Patients With Moderate-to-Severe COPD: The BLAZE Study
    D'Urzo, Anthony
    Mahler, Donald
    Worth, Heinrich
    White, Tracy
    Alagappan, Vijay
    Chen, Hungta
    Kulich, Karoly
    Gallagher, Nicola
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [32] Qva149 Improves Lung Function To A Greater Extent Than Monocomponents In Patients With Moderate-To-Severe COPD: The Flight1 Study
    Kerwin, E. M.
    FowlerTaylor, A.
    Ayers, T.
    Thach, C.
    Maitra, S.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [33] Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study
    Buhl, Roland
    Gessner, Christian
    Schuermann, Wolfgang
    Foerster, Karin
    Sieder, Christian
    Hiltl, Simone
    Korn, Stephanie
    THORAX, 2015, 70 (04) : 311 - +
  • [34] Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis
    Vogelmeier, Claus
    Zhong, Nanshan
    Mezzi, Karen
    Fogel, Robert
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [35] QVA149, Twice Daily, Is Well Tolerated in Patients With Moderate-to-Severe COPD and Has a Safety Profile Similar to Placebo: FLIGHT1 and FLIGHT2 Pooled Analysis in the Subgroup of Patients From the USA
    Ayers, Tim
    Fogel, Robert
    Banerji, Donald
    Maitra, Samopriyo
    Schubert-Tennigkeit, Agnes Annette
    CHEST, 2015, 148 (04)
  • [36] Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
    Roche, Nicolas
    Olsson, Petter
    Vestbo, Jorgen
    FowlerTaylor, Angel
    Ayers, Tim
    Thach, Chau
    Clerkin, Karyn
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [37] Efficacy and Safety of Once-Daily QVA149 Compared With the Free Combination of Its Monocomponents: The BEACON Study
    Dahl, Ronald
    Jadayel, Dalal
    Alagappan, Vijay
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [38] Once-Daily Qva149 Demonstrates Superior Lung Function Compared To Twice-Daily Salmeterol/fluticasone In All Subgroups Of COPD Patients: The Illuminate Study
    Bateman, E. D.
    Vogelmeier, C.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [39] Once-Daily Qva149 Improves Breathlessness And Reduces Rescue Medication Use Compared To Twice-Daily Salmeterol/fluticasone In Patients With COPD: The Illuminate Study
    Bateman, E. D.
    Vogelmeier, C.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [40] Qva149 Provides Superior Improvement In Lung Function Versus Its Monocomponents In Patients With Moderate-To-Severe COPD: The Flight2 Study
    Kerwin, E. M.
    Ayers, T.
    FowlerTaylor, A.
    Larbig, M.
    Thach, C.
    Maitra, S.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
12345